Assembly Biosciences Statistics
Share Statistics
Assembly Biosciences has 7.64M
shares outstanding. The number of shares has increased by 21.69%
in one year.
| Shares Outstanding | 7.64M |
| Shares Change (YoY) | 21.69% |
| Shares Change (QoQ) | 18.05% |
| Owned by Institutions (%) | 0.01% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,674 |
| FTD / Avg. Volume | 10.19% |
Short Selling Information
The latest short interest is 13.21K, so 0.17% of the outstanding
shares have been sold short.
| Short Interest | 13.21K |
| Short % of Shares Out | 0.17% |
| Short % of Float | 0.25% |
| Short Ratio (days to cover) | 1.13 |
Valuation Ratios
The PE ratio is -2.36 and the forward
PE ratio is -2.59.
Assembly Biosciences's PEG ratio is
0.05.
| PE Ratio | -2.36 |
| Forward PE | -2.59 |
| PS Ratio | 3.32 |
| Forward PS | 2.8 |
| PB Ratio | 2.84 |
| P/FCF Ratio | -1.85 |
| PEG Ratio | 0.05 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Assembly Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.42,
with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.42 |
| Quick Ratio | 2.42 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.07 |
| Debt / FCF | -0.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $390,684.93 |
| Profits Per Employee | $-550,369.86 |
| Employee Count | 73 |
| Asset Turnover | 0.24 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 330K |
| Effective Tax Rate | -0.83% |
Stock Price Statistics
The stock price has increased by -9.58% in the
last 52 weeks. The beta is 0.5, so Assembly Biosciences's
price volatility has been higher than the market average.
| Beta | 0.5 |
| 52-Week Price Change | -9.58% |
| 50-Day Moving Average | 11 |
| 200-Day Moving Average | 14.21 |
| Relative Strength Index (RSI) | 61.03 |
| Average Volume (20 Days) | 26,252 |
Income Statement
In the last 12 months, Assembly Biosciences had revenue of 28.52M
and earned -40.18M
in profits. Earnings per share was -6.69.
| Revenue | 28.52M |
| Gross Profit | 28.39M |
| Operating Income | -45.42M |
| Net Income | -40.18M |
| EBITDA | -45.42M |
| EBIT | -45.42M |
| Earnings Per Share (EPS) | -6.69 |
Full Income StatementBalance Sheet
The company has 38.34M in cash and 3.09M in
debt, giving a net cash position of 35.26M.
| Cash & Cash Equivalents | 38.34M |
| Total Debt | 3.09M |
| Net Cash | 35.26M |
| Retained Earnings | -825.92M |
| Total Assets | 99.02M |
| Working Capital | 48.9M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -51.12M
and capital expenditures -28K, giving a free cash flow of -51.15M.
| Operating Cash Flow | -51.12M |
| Capital Expenditures | -28K |
| Free Cash Flow | -51.15M |
| FCF Per Share | -8.52 |
Full Cash Flow StatementMargins
Gross margin is 99.55%, with operating and profit margins of -159.26% and -140.87%.
| Gross Margin | 99.55% |
| Operating Margin | -159.26% |
| Pretax Margin | -139.72% |
| Profit Margin | -140.87% |
| EBITDA Margin | -159.26% |
| EBIT Margin | -159.26% |
| FCF Margin | -179.33% |
